MEET DENISE RICHARDS

 

Hollywood's Denise Richards lost her mother to kidney cancer in 2007. Today, as a director of the Kidney Cancer Association, she's helping to raise awareness of the disease and the need for a cure. Denise invites you to explore the hours of educational videos on this page. There is information here that could help to save your life or the life of someone you love.

2018 17th International Kidney Cancer Symposium

Trump National Doral Miami Hotel, Miami, FL November 2-3, 2018


Cost-Effective Biomarkers Ready at our fingertips


Viraj Master, M.D., Ph.D., FACS

Cell-free DNA (cfDNA)

Neeraj Agarwal, M.D.

RCC Profiling

James J. Hsieh, M.D., Ph.D.

An Empirical Approach to Dissect the TME in RCC

James Brugarolas, M.D., Ph.D.

The impact of the stool microbiome in RCC

Dr. Lisa Derosa, M.D., Ph.D.

Single Cell RNA-Sequencing in RCC

David Braun, M.D., PhD..

Renal mass biopsy in 2018: When, where and how?

Jaime Landman, M.D.

Emerging Ablative Technologies – Whats New And Is It Better?

Timothy McClure, M.D.

Overdiagnosis and the Harms of Overtreatment of Renal Cell Carcinoma

John Leppert, M.D., M.S.

The Radiological Biopsy: Are we there yet? Imaging based renal mass diagnosis

Steven S. Raman, M.D., FSAR FSIR

Pro vs Con for Enucleation

Gopal N. Gupta, M.D., FACS

Enucleation of Renal Mass: Why Would You Not Keep Your Distance?

Alexander Kutikov, M.D., FACS

Laparoscopic Vs Robotic Radical Nephrectomy: What are the Costs and Benefits?

Steven L. Chang, M.D., M.S.

RCC: Putting Frontline Combination Data into Perspective

Michael B. Atkins, M.D.

Metastatic Renal Cell Cancer: Who Deserves Monotherapy?

Primo N Lara, Jr., M.D.

Beyond Checkpoint 
Blockade

Charles G. Drake M.D., Ph.D.

Tayloring Therapy: Therapy Intensification and Discontinuation

Hans Hammers M.D., Ph.D.

Phase II trial of intermittent nivolumab

Moshe C. Ornstein, M.D. MA

Ongoing Clinical Trial Update: A Pilot Study of Pre-surgical Tremelimumab with or without Tissue Cryoablation

Matt Campbell M.D.

Rationally Targeting the Bone with Radium Plus Cabozantinib

Rana R. McKay, M.D.

Treatment-Free Survival Following Discontinuation of First-Line Nivolumab Plus Ipilimumab or Sunitinib

Thomas Powles, M.D., MBBS, FACP

PDIGREE

Tian Zhang, M.D.

Safety and efficacy of checkpoint inhibitors

Nieves Martinez, M.D.

CheckMate 214 Retrospective Analyses

Nizar M. Tannir M.D., FACP

An Evaluation of the Role of Cytoreductive Nephrectomy in Patients with Sarcomatoid RCC

Dr. Andrew W. Silagy

Neoadjuvant PD1 Blockade to Prime the Immune System

Phillip M. Pierorazio, M.D.

Combination Checkpoint Blockade with Surgery

Jose A. Karam, M.D., FACS

What is the Next Cytoreductive Surgical Trial?

Hyung L. Kim, M.D.

Creating Synergy in RCC: Collaborative Approaches to Value

Robert G. Uzzo, M.D.

Engaging Clinical Trialists in the Community Setting

Suzanne Cole, M.D. FACP

Exploiting oncometabolite-induced DNA repair defects

Ranjit S. Bindra, M.D., Ph.D.

Adenosine Pathway Inhibitors

Abhishek Tripathi, M.D.

Neovax: From Translation to Bedside

Thomas Powles M.D., MBBS, MRCP

Targeting Epigenetics and Chromatin Remodeling Genes

Thai H. Ho, M.D.

Neovax: From Translation to Bedside

Toni K. Choueiri, M.D.

Novel metabolic insights into RCC biology and immune response

Ari Hakimi, M.D.

Secreted PD-L1 Splice Variant that Covalently Dimerizes and Mediates Immunosuppression

Kathleen Mahoney, M.D., PH.D.

Targeting Vulnerabilities Arising from Dysregulated Histone Demethylase Function in Kidney Cancer

Abhishek A. Chakraborty, M.D.

Whole Body MRI for Detection of Renal Cell Carcinoma Osseous Metastases

Alberto Diaz de Leon III, M.D.

LARCG Latin American Renal Cancer Group

Rodolfo Reis, M.D, Ph. D.

UPDATES LATIN AMERICAN COOPERATIVE ONCOLOGY GROUP (LACOG)

Andrey Soares, M.D.

Phase 1b study (COSMIC-021) of cabozantinib in combination with atezolizumab:
Results of the dose-escalation stage in 
patients with treatment-naïve advanced 
renal cell carcinoma

Neeraj Agarwal, M.D.

Second-Line VEGFR TKI Outcomes After First-Line Immune Checkpoint Blockade in Metastatic Renal Cell Carcinoma

Ritesh Kotecha, M.D.

Ipilimumab plus Nivolumab as Salvage Therapy in Patients with Checkpoint Inhibitor-Refractory Metastatic Renal Cell Carcinoma

Kimberly Allman, MSN, CNP

2018 Patient & Caregiver Meeting

Sheraton Chicago O’Hare Airport Hotel Rosemont, IL September 22, 2018


Treatment of the Incidental Renal Mass: What are my options and which one is best?

Brian Shuch, M.D.

Management and Outcomes in the Treatment of Locally Advanced Renal Tumors (IVC Thrombus, Role of Lymph Node Dissection, T4 disease)

E. Jason Abel, M.D., FACS

Adjuvant Therapy for Locally Advanced Renal Cell Carcinoma: Status in 2018

Naomi Haas, M.D.

Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma: Status in 2018

Vitaly Margulis, M.D.

What are my options if my cancer comes back in my kidney, where the kidney was, or in the lymph nodes near the kidney? How good are the treatments?

Jose A. Karam, M.D. FACS

Why should I participate in a clinical trial? What’s in it for me?

Susan Demo, Ph.D.

The role of cytoreductive nephrectomy in the treatment of metastatic renal cell carcinoma

Eric Singer, M.D., MA

The role of metastasectomy in the treatment of metastatic renal cell carcinoma

Philippe A. Spiess, M.D, MS, FRCS (C), FACS

What is the best front line treatment for metastatic clear cell renal cell carcinoma in 2018?

Michael Harrison, M.D.

What are the best agents for second line and beyond in the treatment of metastatic clear cell renal cell carcinoma?

Amishi Shah, M.D.

Systemic treatment options for patients with metastatic non-clear cell renal cell carcinoma

Pavlos Msaouel, M.D., Ph.D.

Why does immunotherapy not work for everyone with kidney cancer?

Matthew Campbell, M.D.

Novel combinational therapies: Is the increased toxicity worth the possibility of increased benefit?

Chung-Han (Joe) Lee, M.D., Ph.D.

What novel therapies are on the horizon for metastatic renal cell carcinoma? 2019 and beyond

Mayer Fishman, MD PhD

We'd love to speak with you.